Prati
Julie Tucker
Naslov
Citirano
Citirano
Godina
Purification of a rat neurotensin receptor expressed in Escherichia coli
J TUCKER, R GRISSHAMMER
Biochemical Journal 317 (3), 891-899, 1996
3131996
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, ...
Nature structural biology 9 (10), 745-749, 2002
2782002
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation
RA Ward, C Brassington, AL Breeze, A Caputo, S Critchlow, G Davies, ...
Journal of medicinal chemistry 55 (7), 3285-3306, 2012
1812012
Cyclin-dependent kinases: inhibition and substrate recognition
JA Endicott, MEM Noble, JA Tucker
Current opinion in structural biology 9 (6), 738-744, 1999
1661999
Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer’s disease: design, synthesis, and characterization of pyrazines
S Berg, M Bergh, S Hellberg, K Högdin, Y Lo-Alfredsson, P Söderman, ...
Journal of medicinal chemistry 55 (21), 9107-9119, 2012
1442012
Small molecule binding sites on the Ras: SOS complex can be exploited for inhibition of Ras activation
JJG Winter, M Anderson, K Blades, C Brassington, AL Breeze, C Chresta, ...
Journal of medicinal chemistry 58 (5), 2265-2274, 2015
1322015
How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A
JPI Welburn, JA Tucker, T Johnson, L Lindert, M Morgan, A Willis, ...
Journal of Biological Chemistry 282 (5), 3173-3181, 2007
1282007
First-in-class chemical probes against poly (ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to olaparib
DI James, KM Smith, AM Jordan, EE Fairweather, LA Griffiths, ...
ACS chemical biology 11 (11), 3179-3190, 2016
1262016
Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations
S Wilmes, M Hafer, J Vuorio, JA Tucker, H Winkelmann, S Löchte, ...
Science 367 (6478), 643-652, 2020
1252020
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4, 6-bis anilino pyrimidines
JF Beattie, GA Breault, RPA Ellston, S Green, PJ Jewsbury, CJ Midgley, ...
Bioorganic & medicinal chemistry letters 13 (18), 2955-2960, 2003
1122003
Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 with O6-Substituted Guanine Derivatives
AE Gibson, CE Arris, J Bentley, FT Boyle, NJ Curtin, TG Davies, ...
Journal of medicinal chemistry 45 (16), 3381-3393, 2002
1092002
Structure-based design of protein tyrosine phosphatase-1B inhibitors
E Black, J Breed, AL Breeze, K Embrey, R Garcia, TW Gero, L Godfrey, ...
Bioorganic & medicinal chemistry letters 15 (10), 2503-2507, 2005
1072005
Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor
RA Norman, ST Barry, M Bate, J Breed, JG Colls, RJ Ernill, RWA Luke, ...
Structure 12 (1), 75-84, 2004
1062004
Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4
JA Tucker, T Klein, J Breed, AL Breeze, R Overman, C Phillips, ...
Structure 22 (12), 1764-1774, 2014
982014
Quantitative evaluation of neurotensin receptor purification by immobilized metal affinity chromatography
R Grisshammer, J Tucker
Protein expression and purification 11 (1), 53-60, 1997
931997
Imidazo [1, 2-b] pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors
KF Byth, N Cooper, JD Culshaw, DW Heaton, SE Oakes, CA Minshull, ...
Bioorganic & medicinal chemistry letters 14 (9), 2249-2252, 2004
912004
Aminopyrazinamides: Novel and Specific GyrB Inhibitors that Kill Replicating and Nonreplicating Mycobacterium tuberculosis
PS Shirude, P Madhavapeddi, JA Tucker, K Murugan, V Patil, ...
ACS chemical biology 8 (3), 519-523, 2013
902013
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase
T Klein, N Vajpai, JJ Phillips, G Davies, GA Holdgate, C Phillips, ...
Nature communications 6 (1), 7877, 2015
722015
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA gyrase B
MG Kale, A Raichurkar, SH P, D Waterson, D McKinney, MR Manjunatha, ...
Journal of medicinal chemistry 56 (21), 8834-8848, 2013
652013
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2, 4-bis anilino pyrimidines
GA Breault, RPA Ellston, S Green, SR James, PJ Jewsbury, CJ Midgley, ...
Bioorganic & medicinal chemistry letters 13 (18), 2961-2966, 2003
642003
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20